# US 2012/0252740 A1 · Hdac inhibitors and therapeutic methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252740 A1
- Document ID: US20120252740A1
- Status: Published application
- Kind: A1
- Application number: 13/384,724
- Filed: 2010-07-02
- Published: 2012-10-04
- Earliest claimed: 2009-07-22
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Alan Kozikowski; Kyle V. Butler; Jay H. Kalin
- Web page: https://patentgrep.com/patent/US20120252740A1

## CPC

- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/38: of the suprarenal hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

## Claims

### Claim 1

A compound having a structural formula
wherein ring
is an aliphatic or aromatic five- or six-membered ring;
D, E, and F, independently, are selected from the group consisting of C(Ra)2, O, S, and NRa;
G is selected from the group consisting of null, C(Ra)2, O, S, NRa, C(Ra)2—C(Ra)2, NRa—C(Ra)2, NRa—NRa, C(Ra)2—O, and C(Ra)2—S;
R0, independently, is selected from the group consisting of C1-6alkyl, C1-6heteroalkyl, C2-6alkenyl, C1-6perfluoroalkyl, C1-6perfluoroalkoxy, aryl, heteroaryl, C3-10cycloalkyl, C3-8heterocycloalkyl, C1-6alkylenearyl, C1-6alkyleneheteroaryl, C1-6alkyleneheterocycloalkyl, C1-6alkylenecycloalkyl,
ORb, halo, N(Rb)2, SRb, SORb, SO2Rb, CN, C(═O)Rb, OC(═O)Rb, C(═O)ORb, C1-6alkyleneN(Rb)2, C1-6alkyleneORb, C1-6alkyleneSRb, C1-6alkyleneC(═O)ORb, C(═O)N(Rb)2, C(═O)NRbC1-6alkyleneORb, OC1-6-alkyleneC(═O)ORb, OC1-6alkyleneN(Rb)2, OC1-6alkyleneORb, OC1-6alkyleneNRbC(═O)ORb, NRbC1-6alkyleneN(Rb)2, NRbC(═O)Rb, NRbC(═O)N(Rb)2, N(SO2C1-6alkyl)2, NRb(SO2C1-6alkyl), nitro, and SO2N(Rb)2;
m is an integer 0, 1, 2, 3, or 4;
Ra, independently, is selected from the group consisting of null, hydrogen, C1-6alkyl, C2-6alkenyl, C1-6heteroalkyl, aryl, heteroaryl, C3-8cycloalkyl, C3-10heterocycloalkyl, C1-6alkylenearyl, C1-6alkyleneheteroaryl, C1-6alkyleneC(═O)ORb, C1-6alkyleneC(═O)Rb, C1-6alkyleneC(═O)N(Rb)2, C(═O)Rb, C(═O)N(Rb)2, C(═O)ORb, CN, ORb, halo, N(Rb)2, SRb, SORb, SO2Rb, CF3, OCF3, NO2, OC(═O)Rb, OC1-6alkyleneC(═O)ORb, C1-6alkyleneOC1-6alkyleneC(═O)ORb, C(═O)NRbSO2Rb, C(═O)C1-6alkylenearyl, C1-6alkyleneN(Rb)2, C1-6alkyleneORb, C1-6alkyleneSRb, C(═O)NRbC1-6alkyleneORb, OC1-6alkyleneN(Rb)2, OC2-6alkyleneORb, OC2-6alkyleneNRbC(═O)ORb, NRbC1-6alkyleneN(Rb)2, NRbC(═O)Rb, NRbC(═O)N(Rb)2, N(SO2C1-6alkyl)2, NRb(SO2C1-6alkyl), SO2N(Rb)2, and OSO2CF3;
Rb, independently, is selected from the group consisting of hydrogen, C1-6alkyl, C1-6heteroalkyl, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)2, C1-6alkyleneNH(C1-6alkyl)2, C1-6alkyleneOH, C1-6alkyleneOC1-6alkyl, C1-6alkyleneSH, C1-6alkyleneSC1-6alkyl, aryl, heteroaryl, C3-8cycloalkyl, and C3-10heterocycloalkyl;
Y is selected from the group consisting of null, C1-8alkylene, Ra substituted C1-8alkylene, NRb, C(═O), aryl, C(═O)aryl, C(═O)C1-6alkylene, C1-8alkyleneNRb, C1-6alkylenearyleneC1-6alkylene, C2-6alkenylene, C4-8alkdienylene, C1-6alkylenearylene, C1-6alkyleneheteroarylene, Ra substituted C1-6alkyleneheteroarylene, and C2-6alkenylenearyleneC1-6alkylene;
Z is selected from the group consisting of —C(═O)N(Rc)OH,
—O(CH2)1-6C(═O)N(Rc)ORb,
—N(Rc)(CH2)1-6C(═O)N(Rc)ORc,
arylC(═O)NHOH,
—N(OH)C(═O)Rc,
heteroarylC(═O)NHOH,
—B(ORc)2,
—SO2NHRc,
—NHSO2NHRc,
—NHSO2C1-6alkyl,
—SO2C1-6alkyl,
—P(═O)(ORg)2, wherein Rg independently is hydrogen, methyl, or ethyl,
—NH—P(═O)(ORg)2,
—C(═O)Rf wherein Rf is selected from the group consisting of OH, N(Rc)2, NH(OCH3), N(CH3)OH, C1-6alkyl, CF3, aryl, heteroaryl, C3-8cycloalkyl, NHSO2CH3, NHSO2CF3, and C1-6haloalkyl,
—C(═O)(C(Rc)2)1-6SH,
—C(═O)C(═O)NHRc, —C(═O)NHN(Rc)2,
—C(═O)NH(CH2)1-3N(Rc)2,
—SRd wherein Rd is hydrogen or (C═O)CH3,
—S—(C═O)C1-6alkyl,
C3-10heterocycloalkyl optionally substituted with oxo (═O), thioxo (═S), or both,
aryl optionally substituted with one or more of C1-6alkyl, —C(═O)Re, —NH2, and —SH,
heteroaryl optionally substituted with —NH2, —SH, or both,
—N(H)C(═O)SH,
—NHC(═O)NHRe,
—NHC(═O)CH2Re,
—NHC(═O)(CH2)1-6SH,
—NHC(═O)CH2Hal,
—NHC(═S)NHRe,
—NHC(═S)CH2Re,
—C(═S)NHRe,
—C(═S)CH2Re,
—NHC(═S)CH2Re,
—NHC(═S)CH2Hal, and
—(C═O)C1-6alkyl;
Rc, independently, is selected from the group consisting of hydrogen, (C═O)CH3, C1-6alkyl, CF3, CH2F, and aryl, or two Rc groups are taken together with the carbon to which they attached to form a C3-8cycloalkyl group; and
Re is NH2 or OH;
or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein
is selected from the group consisting of cyclohexyl, cyclohexenyl, cyclopentyl, cyclopentenyl, cycloheptyl, cycloheptenyl, phenyl, furanyl, 2H-pyrrolyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3,-triazolyl, 1,2,5-oxadiazolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, oxazolyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, 3H-pyrrolyl, 5H-1,2,5-oxathiazolyl, 1,3-oxathiolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyrimidinyl, piperazinyl, 2-pyronyl, 4-pyronyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 6H-1,2-oxazinyl, 4H-1,4-oxazinyl, 1,4-oxazinyl, p-isoxazinyl, o-isoxazinyl, pyridinyl, pyridazinyl, pyrazinyl, azacycloheptyl, azacycloheptenyl, oxacycloheptyl, and thiacycloheptyl.

### Claim 3 (depends on 1)

The compound of claim 1 wherein
is selected from the group consisting of

### Claim 4 (depends on 1)

The compound of claim 1 wherein
is selected from the group consisting of

### Claim 5 (depends on 1)

The compound of claim 1 wherein m is 0, 1, or 2.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R0 is selected from the group consisting of ORb, halo, C1-6alkyl, aryl, heterocycloalkyl, —(CH2)1-4heterocycloalkyl, —(CH2)1-4N(Rb)2,
and —C(═O)N(CH2)1-4N(Rb)2.

### Claim 7 (depends on 1)

The compound of claim 1 wherein Ra and Rb, independently, are selected from the group consisting of C1-6alkyl, halo, C1-3alkylenearyl, C1-3alkyleneheteroaryl, C1-3alkyleneneheterocycloalkyl, C(═O)C1-3alkyl, C2-6alkenyl, BOC, C1-3 alkyleneC(═O)NH2,
and C1-3alkyleneC(═O)OH.

### Claim 8

The compound of group 1 wherein Y is null, —(CH2)1-6—,
optionally substituted with halo, CF3, or CN,

### Claim 9 (depends on 1)

The compound of claim 1 wherein Z is

### Claim 10

A compound selected from the group consisting of compounds disclosed in paragraph [0200] herein.

### Claim 11 (depends on 1)

The compound of claim 1 having a structure

### Claim 12 (depends on 1)

A composition comprising (a) compound of claim 1, (b) a second therapeutic agent useful in the treatment of a disease or condition wherein inhibition of HDAC provides a benefit, and (c) an optional excipient and/or pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12 wherein the second therapeutic agent is useful in the treatment of an autoimmune disease or inflammation.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method of treating a disease or condition wherein inhibition of HDAC provides a benefit comprising administering a therapeutically effective amount of a compound of claim 1 to an individual in need thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein the HDAC is HDAC6.

### Claim 17 (depends on 15)

The method of claim 15 further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease or condition.

### Claim at position 18

-25. (canceled)

### Claim 26 (depends on 15)

The method of claim 15 wherein the disease or condition is a neurological disease, a neurodegenerative disorder, or a traumatic brain injury.

### Claim 27 (depends on 26)

The method claim 26 wherein the disease or condition is selected from a disease or condition disclosed in paragraphs [0341]-[0344] and [0346] herein.

### Claim 28 (depends on 15)

The method of claim 15 wherein the disease or condition is a stroke.

### Claim 29 (depends on 15)

The method of claim 15 wherein the disease or condition is an inflammation or an autoimmune disease.

### Claim 30 (depends on 29)

The method of claim 29 wherein the autoimmune disease or inflammation is selected from a condition disclosed in paragraph [0364] and [0365].

### Claim 31 (depends on 29)

The method of claim 29 further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the autoimmune disease or inflammation.

### Claim 32 (depends on 31)

The method of claim 31 wherein the second therapeutic agent is selected from the agents disclosed in paragraph [0363] and [0366].

### Claim 33 (depends on 15)

The method of claim 15 wherein the disease or condition is disclosed in paragraph [0097].

### Claim at position 27

-38. (canceled)

### Claim 39 (depends on 15)

The method of claim 15 wherein the disease or condition is autism.

### Claim at position 29

40-45. (canceled)
